Homeland security, homeland profitability

["Charles Jannuzi" <jannuzi@xxxxxxxxxxxxxxxxxxxxxxxxx>]

This makes interesting reading if you want to see who is lining up for the
38 billion dollars going to the homeland security budget:

http://www.cq.com/homeland/hsse.pdf

Rumsfeld has had to make some important decisions. One, before 9-11, was
whether or not to stop the current anthrax vaccine program (which was
centered on BioPort and a couple other biotech startups). I don't know where
Rumsfeld's portfolio is invested, but it seems likely to be with
pharmaceuticals (he was the head of one firm that is now part of the
enormous Pharmacia) and defense, which finds a nifty convergence in stuff
that is anthrax-related (because of the vaccine development programs and
treatments against nuclear, biological and chemical--NBC-- warfare agents).

Here is one example which, if nothing else, probably shows that for testing
purposes the distribution of weaponized anthrax was never as controlled as
we thought, though this venture is at pains to point out that they use other
bacillus to test:

http://www.cyclopss.com/news/pharma1.html



Cyclopss Completes First Phase Of Pharmacia Decontamination System

Salt Lake City, UT (November 13, 2001) - Cyclopss Corporation (Symbol OZON,
OTC) announced today that it has completed the first phase of a
decontamination system development contract with the New Jersey based
pharmaceutical company PHARMACIA (Symbol PHA, NYSE). Cyclopss is utilizing a
proprietary ozone technology to develop a new process for the
decontamination, disinfection and aseptic maintenance in the manufacturing
and packaging of certain of PHARMACIA'S products. With the initial proof of
concept phase completed the contract will proceed through two more phases,
the construction and testing of the Pathfinder Prototype System, and finally
a fully functional Ster-O-Zone system that will be validated in plant by
PHARMACIA.

The PHARMACIA system is being designed to destroy all dangerous pathogens,
including Bacillus Subtilis and Bacillus Stearothermophilus spores which are
from the same genus as Bacillus Anthracis, the viral spore that causes
Anthrax. "The Bacillus family of spores have long been identified by the FDA
as the most difficult of spores to kill," says Dr. Durand Smith, President
and Director of R&D at Cyclopss. He continues, "These Anthrax surrogates are
regularly used in biological studies to reduce the danger to
microbiologists. The government study regarding ozone's effect on Anthrax,
undertaken at Los Alamos Laboratories, used yet another look alike spore
from the genus, Bacillus Globigii."

Management stated that one of the primary interests driving the potential
for the use of ozone technology by the pharmaceutical manufacturing, and
packaging industry, is the fact that it creates only oxygen as a by-product
of its killing action, leaving no other residual chemicals behind to
potentially interact or degrade the sometimes sensitive pharmaceutical
products.

CYCLOPSS announced late last month that it had completed a development and
installation contract for a Ster-O-Zone ozone decontamination chamber for a
nationally recognized biological testing lab. This product was also designed
to destroy all pathogens including not less than 99.9% of Bacillus spores.
In this system, laboratory carts and equipment used in biological testing
are wheeled into a stainless steel chamber and treated with ozone gas for 30
minutes. The chamber has recently demonstrated the ability to effectively
destroy these spores on mail that may have been cross contaminated from
postal equipment that has come in contact with Anthrax laden letters.

Management further stated, that while the development of both of these
products was underway long before the current Anthrax threat, they may prove
to be very timely and effective weapons in the war against Bioterrorism.

CYCOPSS is a world leader in the development of environmentally friendly
technologies and applications that are used in the cleaning and disinfection
of foods, laundry, and surfaces for industries as well as consumers.

Back to Cyclopss News

Copyright ï 1997-2000, Cyclopss Corporation, All Rights Reserved. Questions
or Comments? Email to info@xxxxxxxxxxxx | Terms of Use